Kurma Partners
Europe-focused investment manager financing innovation across healthcare and life sciences. Activities include venture creation and funding for therapeutics, diagnostics, medtech and digital health from seed to growth stages; active portfolio operational support covering clinical and manufacturing de-risking, quality and regulatory coordination; and integration of ESG and sustainability practices into investment processes and reporting.
Industries
Nr. of Employees
small (1-50)
Kurma Partners
Products
Kurma Biofund IV
Investment fund dedicated to therapeutic solutions and company creation across high unmet medical needs. First closing reported at €140M toward a target size of €250M (fund sustainability positioning disclosed).
Kurma Growth Opportunities Fund
Fund focused on growth capital investments across therapeutics, diagnostics, healthtech and medtech including late-stage and crossover rounds.
Kurma Diagnostics funds (KDx)
Funds dedicated to seed and early-stage investments in diagnostics, genomic testing and digital health solutions to accelerate technical validation and commercialisation.
Kurma Biofund III (historical fund)
Prior generation therapeutics fund used to finance earlier portfolio company formation and clinical development investments.
Kurma Biofund IV
Investment fund dedicated to therapeutic solutions and company creation across high unmet medical needs. First closing reported at €140M toward a target size of €250M (fund sustainability positioning disclosed).
Kurma Growth Opportunities Fund
Fund focused on growth capital investments across therapeutics, diagnostics, healthtech and medtech including late-stage and crossover rounds.
Kurma Diagnostics funds (KDx)
Funds dedicated to seed and early-stage investments in diagnostics, genomic testing and digital health solutions to accelerate technical validation and commercialisation.
Kurma Biofund III (historical fund)
Prior generation therapeutics fund used to finance earlier portfolio company formation and clinical development investments.
Services
Operational support for portfolio companies including scientific and clinical strategy, regulatory coordination, data protection guidance, and facilitation of CDMO and manufacturing partnerships.
Fund-level support for sustainability integration including sustainability due diligence, materiality assessments, integration of ESG clauses in legal documentation, sustainability reporting and decarbonization planning.
Operational support for portfolio companies including scientific and clinical strategy, regulatory coordination, data protection guidance, and facilitation of CDMO and manufacturing partnerships.
Fund-level support for sustainability integration including sustainability due diligence, materiality assessments, integration of ESG clauses in legal documentation, sustainability reporting and decarbonization planning.
Expertise Areas
- Venture creation and seed funding for life sciences
- Growth capital and late-stage financing for healthcare companies
- Diagnostics and molecular testing (assays, instruments, NGS and dPCR)
- Clinical development financing and trial progression support
Key Technologies
- Next-generation sequencing (NGS) for quality control and diagnostics
- Digital PCR (dPCR) and quantitative molecular assays
- AI/ML for diagnostics and clinical decision support
- Cloud-based healthcare data architectures and interoperability
News & Updates
Announcement that a portfolio genomic quality control laboratory received GLP certification for biologics genomic testing services, supporting NGS-based biosafety testing for biopharma quality control.
Financing to support deployment of data architecture and interoperability solutions for healthcare providers across France and Europe.
Financing extension to support commercial launch of a benchtop enzymatic DNA printing platform to accelerate molecular biology and genomics workflows.
Financing round to support development and commercialisation of digital PCR instruments and high-precision genetic analysis solutions.
Financing to accelerate development of a culture-free diagnostic solution for early sepsis identification and commercial deployment.
Seed financing to support development of a liquid biopsy tool aimed at simplifying sample collection and processing for precision diagnostics.
Announcement that a portfolio genomic quality control laboratory received GLP certification for biologics genomic testing services, supporting NGS-based biosafety testing for biopharma quality control.
Financing to support deployment of data architecture and interoperability solutions for healthcare providers across France and Europe.
Financing extension to support commercial launch of a benchtop enzymatic DNA printing platform to accelerate molecular biology and genomics workflows.
Financing round to support development and commercialisation of digital PCR instruments and high-precision genetic analysis solutions.
Financing to accelerate development of a culture-free diagnostic solution for early sepsis identification and commercial deployment.
Seed financing to support development of a liquid biopsy tool aimed at simplifying sample collection and processing for precision diagnostics.